PriceTargets.com logo

Replimune Group - REPL Stock Price Target and Predictions

  • Consensus Rating: Reduce
  • Consensus Price Target: $4.75
  • Forecasted Upside: 90.00%
  • Number of Analysts: 10
  • Breakdown:
  • 4 Sell Ratings
  • 6 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.50 As of 05/1/2026 05:00 PM ET
▼ -0.07 (-2.72%)

This chart shows the closing price for REPL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Replimune Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for REPL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for REPL

Analyst Price Target is $4.75
▲ +90.00% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Replimune Group in the last 3 months. The average price target is $4.75, with a high forecast of $12.00 and a low forecast of $2.00. The average price target represents a 90.00% upside from the last price of $2.50.

This chart shows the closing price for REPL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Reduce

The current consensus among 10 contributing investment analysts is to reduce stock in Replimune Group. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/9/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/7/2025
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/8/2025
  • 1 strong buy ratings
  • 2 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
8/6/2025
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 2 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 2 sell ratings
Ratings as of
2/2/2026
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 2 sell ratings
Ratings as of
4/3/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 4 sell ratings
Ratings as of
5/3/2026

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 4 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/24/2026Weiss RatingsDowngradeSell (D-) ➝ Sell (E+)
4/13/2026Cantor FitzgeraldDowngradeOverweight ➝ Hold
4/13/2026BMO Capital MarketsDowngradeMarket Perform ➝ Underperform
4/13/2026Leerink PartnersReiterated RatingOutperform ➝ Market Perform$11.00 ➝ $2.00
4/13/2026Jefferies Financial GroupReiterated RatingBuy ➝ Hold$13.00 ➝ $2.00
4/13/2026WedbushReiterated RatingOutperform ➝ Neutral$19.00 ➝ $2.00
4/13/2026JPMorgan Chase & Co.Reiterated RatingNeutral ➝ Underweight
4/13/2026HC WainwrightReiterated RatingBuy ➝ Sell
4/10/2026Piper SandlerDowngradeOverweight ➝ Neutral$4.00
2/5/2026Piper SandlerBoost TargetOverweight ➝ Overweight$13.00 ➝ $14.00
2/4/2026WedbushBoost TargetOutperform ➝ Outperform$18.00 ➝ $19.00
12/29/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/22/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/15/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/24/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/17/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/11/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/5/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/27/2025HC WainwrightUpgradeNeutral ➝ Buy$12.00
10/20/2025Piper SandlerUpgradeNeutral ➝ Overweight$13.00
10/20/2025JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$11.00
10/20/2025Leerink PartnersUpgradeMarket Perform ➝ Outperform$3.00 ➝ $13.00
10/20/2025WedbushUpgradeNeutral ➝ Outperform$4.00 ➝ $18.00
10/14/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/19/2025JPMorgan Chase & Co.Reiterated RatingNeutral ➝ Underweight
9/8/2025HC WainwrightReiterated RatingNeutral ➝ Neutral
7/30/2025Cantor FitzgeraldUpgradeNeutral ➝ Overweight
7/23/2025BarclaysDowngradeOverweight ➝ Equal Weight$17.00 ➝ $3.00
7/23/2025BMO Capital MarketsDowngradeOutperform ➝ Underperform$27.00 ➝ $2.00
7/23/2025HC WainwrightDowngradeBuy ➝ Neutral
7/22/2025Leerink PartnersDowngradeStrong-Buy ➝ Hold
7/22/2025Cantor FitzgeraldDowngradeStrong-Buy ➝ Hold
7/22/2025Jefferies Financial GroupLower TargetBuy ➝ Buy$31.00 ➝ $6.00
7/22/2025Leerink PartnersReiterated RatingOutperform ➝ Market Perform$21.00 ➝ $3.00
7/22/2025JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Neutral$19.00 ➝ $9.00
7/22/2025Piper SandlerDowngradeOverweight ➝ Neutral$3.00
7/22/2025WedbushReiterated RatingOutperform ➝ Neutral$19.00 ➝ $4.00
7/16/2025JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$16.00 ➝ $19.00
7/3/2025HC WainwrightReiterated RatingBuy ➝ Buy$22.00
6/20/2025Cantor FitzgeraldInitiated CoverageOverweight
6/2/2025Piper SandlerBoost TargetOverweight ➝ Overweight$14.00 ➝ $22.00
2/26/2025JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$16.00 ➝ $18.00
2/13/2025HC WainwrightBoost TargetBuy ➝ Buy$21.00 ➝ $22.00
1/22/2025BMO Capital MarketsBoost TargetOutperform ➝ Outperform$18.00 ➝ $27.00
1/22/2025HC WainwrightBoost TargetBuy ➝ Buy$17.00 ➝ $21.00
12/4/2024Jefferies Financial GroupBoost TargetBuy ➝ Buy$16.00 ➝ $19.00
11/22/2024BMO Capital MarketsBoost TargetOutperform ➝ Outperform$14.00 ➝ $18.00
11/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$17.00 ➝ $17.00
11/12/2024HC WainwrightReiterated RatingBuy ➝ Buy$17.00 ➝ $17.00
9/24/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$14.00 ➝ $17.00
9/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$17.00 ➝ $17.00
9/10/2024HC WainwrightReiterated RatingBuy ➝ Buy$17.00 ➝ $17.00
8/27/2024Roth MkmUpgradeStrong-Buy
8/27/2024Roth MkmInitiated CoverageBuy$17.00
8/13/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$17.00 ➝ $14.00
6/7/2024BarclaysBoost TargetOverweight ➝ Overweight$13.00 ➝ $17.00
6/7/2024HC WainwrightBoost TargetBuy ➝ Buy$12.00 ➝ $17.00
6/6/2024WedbushReiterated RatingOutperform$16.00
12/6/2023BarclaysLower TargetOverweight ➝ Overweight$50.00 ➝ $13.00
11/13/2023HC WainwrightLower TargetBuy ➝ Buy$50.00 ➝ $48.00
11/8/2023WedbushReiterated RatingOutperform ➝ Outperform$52.00
8/7/2023HC WainwrightLower TargetBuy ➝ Buy$51.00 ➝ $50.00
8/1/2023HC WainwrightReiterated RatingBuy ➝ Buy$51.00
6/5/2023HC WainwrightBoost Target$50.00 ➝ $51.00
4/17/2023Piper SandlerReiterated RatingOverweight$44.00
2/10/2023HC WainwrightBoost TargetBuy$48.00 ➝ $50.00
12/14/2022Piper SandlerBoost Target$43.00 ➝ $58.00
12/12/2022BMO Capital MarketsBoost TargetOutperform$40.00 ➝ $70.00
12/7/2022Leerink PartnersBoost TargetOutperform$30.00 ➝ $34.00
11/4/2022HC WainwrightLower TargetBuy$60.00 ➝ $48.00
10/14/2022BMO Capital MarketsBoost TargetOutperform$30.00 ➝ $40.00
10/3/2022Leerink PartnersLower TargetOutperform$37.00 ➝ $30.00
8/22/2022Piper SandlerLower Target$43.00
8/16/2022Piper SandlerLower TargetOverweight$44.00 ➝ $43.00
8/5/2022Leerink PartnersLower TargetOutperform$48.00 ➝ $37.00
5/24/2022HC WainwrightReiterated RatingBuy$60.00
5/24/2022WedbushLower TargetOutperform$59.00 ➝ $52.00
5/20/2022Leerink PartnersLower TargetOutperform$49.00 ➝ $48.00
5/19/2022Piper SandlerLower Target$52.00 ➝ $44.00
4/4/2022JPMorgan Chase & Co.Lower TargetOverweight$47.00 ➝ $39.00
3/18/2022BMO Capital MarketsLower TargetOutperform$51.00 ➝ $30.00
1/11/2022HC WainwrightReiterated RatingBuy$60.00
11/19/2021Piper SandlerInitiated CoverageOverweight$52.00
11/15/2021HC WainwrightReiterated RatingBuy$59.00
10/15/2021BTIG ResearchInitiated CoverageBuy$60.00
8/23/2021Leerink PartnersLower TargetOutperform$55.00 ➝ $49.00
8/9/2021HC WainwrightReiterated RatingBuy$60.00
8/9/2021Leerink PartnersLower TargetOutperform$56.00 ➝ $55.00
(Data available from 5/3/2021 forward)

News Sentiment Rating

0.01 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 76 positive mentions
  • 7 negative mentions
  • 2 very negative mentions
Mentions as of
10/5/2025
  • 6 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
12/4/2025
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/3/2026
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/2/2026
  • 0 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/4/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2026
  • 10 very positive mentions
  • 23 positive mentions
  • 12 negative mentions
  • 8 very negative mentions
Mentions as of
5/3/2026

Current Sentiment

  • 10 very positive mentions
  • 23 positive mentions
  • 12 negative mentions
  • 8 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Replimune Group logo
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Read More

Today's Range

Now: $2.50
Low: $2.39
High: $2.61

50 Day Range

MA: $6.01
Low: $1.70
High: $8.64

52 Week Range

Now: $2.50
Low: $1.50
High: $13.24

Volume

3,468,377 shs

Average Volume

10,990,799 shs

Market Capitalization

$206.43 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.12

Frequently Asked Questions

What sell-side analysts currently cover shares of Replimune Group?

The following Wall Street research analysts have issued research reports on Replimune Group in the last twelve months: Barclays PLC, BMO Capital Markets, Cantor Fitzgerald, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., Leerink Partners, Piper Sandler, Wall Street Zen, Wedbush, and Weiss Ratings.
View the latest analyst ratings for REPL.

What is the current price target for Replimune Group?

0 Wall Street analysts have set twelve-month price targets for Replimune Group in the last year. Their average twelve-month price target is $4.75, suggesting a possible upside of 90.0%. HC Wainwright has the highest price target set, predicting REPL will reach $12.00 in the next twelve months. BMO Capital Markets has the lowest price target set, forecasting a price of $2.00 for Replimune Group in the next year.
View the latest price targets for REPL.

What is the current consensus analyst rating for Replimune Group?

Replimune Group currently has 4 sell ratings and 6 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Reduce."
View the latest ratings for REPL.

What other companies compete with Replimune Group?

Other companies that are similar to Replimune Group include Esperion Therapeutics, Relmada Therapeutics, Eton Pharmaceuticals, Hyperliquid Strategies and Kura Oncology. Learn More about companies similar to Replimune Group.

How do I contact Replimune Group's investor relations team?

Replimune Group's physical mailing address is 500 Unicorn Park, WOBURN MA, 01801. The company's listed phone number is (781) 222-9600 and its investor relations email address is [email protected]. The official website for Replimune Group is www.replimune.com. Learn More about contacing Replimune Group investor relations.